Viagenpumatucel-L - Heat Biologics

Drug Profile

Viagenpumatucel-L - Heat Biologics

Alternative Names: Ad100-gp96Ig-HLA A1; Gp96-Ig and HLA A1 transfected Non-Small Cell Lung Cancer cell line; gp96-Ig lung cancer vaccine - Heat Biologics/University of Miami; HS-110; HS-L1

Latest Information Update: 05 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Miami
  • Developer Heat Biologics
  • Class Adjuvants; Cancer vaccines
  • Mechanism of Action Heat-shock protein stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 Apr 2018 Heat Biologics plans a phase III trial in Non small cell lung cancer in the third quarter of 2019
  • 28 Feb 2018 Interim efficacy adverse events data from a phase Ib/II DURGA trial in Non-small cell lung cancer released by Heat Biologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top